Laboratory Products

  • Extended CRISPR Screening Service to Primary Human T Cells Announced

Extended CRISPR Screening Service to Primary Human T Cells Announced

Jan 23 2019 Read 243 Times

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, has announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery, enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.

CRISPR screens in primary T lymphocytes have proved challenging, owing to complex issues around the introduction of the screening components and Cas9 in particular. Horizon has adapted its established CRISPRko (knockout) platform to address these issues and to deliver a robust screening platform in human T lymphocytes, which will enable complex biological processes, novel targets and more effective drug therapies to be investigated in a therapeutically relevant cell type.

Horizon has added CRISPRko screens in ex vivo T lymphocytes to its established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines. The Company’s extension of its CRISPRko Screening Service strengthens its existing immuno-oncology platform and reinforces its commitment to supporting researchers working in this rapidly growing field of research.

Terry Pizzie, Chief Executive Officer, Horizon Discovery Group, commented: “The successful demonstration of primary human T cells in Horizon’s CRISPR screening platforms is a breakthrough format for our clients working in the immuno-oncology space; enabling them to find gene targets and potential therapeutic avenues in an immediately biologically relevant setting rather than having to work through surrogate cell lines. We expect that this approach will allow our customers to save considerable time and resources in downstream validation, helping them to get therapeutics to the clinic faster.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Lab Asia April 2019

April 2019

In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - VMXm takes its First Users 'wher...

View all digital editions

Events

InformEx

Apr 30 2019 Chicago, IL, USA

Making Pharmaceuticals Exhibition & Conference 2019

Apr 30 2019 Ricoh Arena, Coventry, UK

AOCS Annual Meeting & Expo

May 05 2019 St. Louis, MO, USA

ISCC & GCxGC 2019

May 13 2019 Fort Worth, Tx, USA

ISHM 2019

May 14 2019 Oklahoma, USA

View all events